2-Minute Neuroscience: Agonism, Antagonism, & Allosteric Modulation
64.9 هزار بار بازدید -
4 سال پیش
-
Drugs can interact with receptors
Drugs can interact with receptors in a number of different ways, which are typically categorized as various types of agonism, antagonism, or allosteric modulation. In this video, I describe these drug-receptor interactions.
TRANSCRIPT:
Agonism occurs when a drug binds to a receptor and causes a biological response. Agonist drugs typically bind to the same place on the receptor as the substance that naturally activates the receptor, or the endogenous agonist. Agonists that can generate a maximal response at a receptor are called full agonists. Partial agonists are only able to generate a fraction of the possible response at a receptor. In some cases, an agonist may bind to a receptor and cause a decrease in signaling at that receptor. These substances are called inverse agonists, and they can produce effects that are opposite to those of an agonist.
Receptor antagonism occurs when a drug binds to a receptor but does not activate the receptor; in the process, it interferes with the ability of agonists to activate the receptor. The most common type of antagonism is reversible competitive antagonism, where a drug competes with an agonist for its binding site, in the process limiting the amount of agonist that can bind to the receptor at the same time. Reversible competitive antagonists frequently unbind and rebind to receptors. An agonist can replace the antagonist while it is unbound, allowing the antagonist’s effects to be overcome with the addition of more agonist. Irreversible competitive antagonists, sometimes called non-competitive antagonists, also bind to the site where an agonist binds but unbind from the receptor very slowly, if at all. They can reduce the maximal effect an agonist has, regardless of how much agonist is present.
Some drugs may bind to a receptor at a different site from where an agonist binds and influence the function of the receptor. These drugs, often called allosteric modulators, may increase or decrease the likelihood of an agonist binding to a receptor, enhance or reduce the effects an agonist has when it does bind, or activate the receptor on their own.
References:
Neubig RR, Spedding M, Kenakin T, Christopoulos A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003 Dec;55(4):597-606.
Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang & Dale's Pharmacology. 9th ed. New York, NY: Elsevier; 2020.
TRANSCRIPT:
Agonism occurs when a drug binds to a receptor and causes a biological response. Agonist drugs typically bind to the same place on the receptor as the substance that naturally activates the receptor, or the endogenous agonist. Agonists that can generate a maximal response at a receptor are called full agonists. Partial agonists are only able to generate a fraction of the possible response at a receptor. In some cases, an agonist may bind to a receptor and cause a decrease in signaling at that receptor. These substances are called inverse agonists, and they can produce effects that are opposite to those of an agonist.
Receptor antagonism occurs when a drug binds to a receptor but does not activate the receptor; in the process, it interferes with the ability of agonists to activate the receptor. The most common type of antagonism is reversible competitive antagonism, where a drug competes with an agonist for its binding site, in the process limiting the amount of agonist that can bind to the receptor at the same time. Reversible competitive antagonists frequently unbind and rebind to receptors. An agonist can replace the antagonist while it is unbound, allowing the antagonist’s effects to be overcome with the addition of more agonist. Irreversible competitive antagonists, sometimes called non-competitive antagonists, also bind to the site where an agonist binds but unbind from the receptor very slowly, if at all. They can reduce the maximal effect an agonist has, regardless of how much agonist is present.
Some drugs may bind to a receptor at a different site from where an agonist binds and influence the function of the receptor. These drugs, often called allosteric modulators, may increase or decrease the likelihood of an agonist binding to a receptor, enhance or reduce the effects an agonist has when it does bind, or activate the receptor on their own.
References:
Neubig RR, Spedding M, Kenakin T, Christopoulos A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003 Dec;55(4):597-606.
Ritter JM, Flower R, Henderson G, Loke YK, MacEwan D, Rang HP. Rang & Dale's Pharmacology. 9th ed. New York, NY: Elsevier; 2020.
4 سال پیش
در تاریخ 1399/02/07 منتشر شده
است.
64,915
بـار بازدید شده